Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | BAX | Q07812 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PNLIP | P16233 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15079886 | 0.88 | LMNA (0.39) | LTA4HSMN1; SMN2HRH3 | |
| SCHEMBL15079366 | 0.84 | KDM4E (0.44) | LTA4HSMN1; SMN2TSHRPOLB | |
| SCHEMBL15079895 | 0.84 | ATF4 (0.40) | TSHRPOLB | |
| SCHEMBL15079426 | 0.84 | CYP26A1 (0.34) | SMN1; SMN2MAOB | |
| SCHEMBL15079790 | 0.84 | PKM (0.51) | TSHR | |
| SCHEMBL15079779 | 0.82 | MAOB (0.44) | SMN1; SMN2TSHRMAOBHRH3 | |
| SCHEMBL15079775 | 0.82 | MAPT (0.39) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL15079856 | 0.81 | MEN1 (0.45) | MAOBAOC3L3MBTL1 | |
| SCHEMBL15079756 | 0.81 | KMT2A (0.39) | SMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL15079849 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRMAOBAOC3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2015-01-01 | — | — | US | disclosed |
| WO-2013093320-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | DIVERCHIM (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004110-A1 | NOVEL ANTI-AGING AND DEPIGMENTING COSMETIC COMPOSITIONS | ARG1, TYR, NOS1 | LTA4H 273/4885NR1H2 555/4885BAX 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.